Clinical Trial Update: Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates erlotinib hydrochloride alone or in combination with cabozantinib-s-malate as second- or third-line therapy for stage IV non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2016-12-01